Aquestive stock: buy or sell?
January 17th, 2020
Should I buy Aquestive stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Aquestive Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Aquestive Therapeutics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 4 ratings published for AQST stock in the last month. The general sentiment of these ratings is bullish for AQST stock, with 4 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-15||BMO Capital Markets||In-Line||Outperform|
|2019-2-20||Lake Street Capital||n/a||Buy|
Aquestive stock analysis
After sliding a chilling -5.31% on Jan/16, Aquestive Therapeutics closed yesterday at $4.10 and depreciated a bad -0.97%.
After sliding a chilling -5.31% on Jan/16, Aquestive Therapeutics closed yesterday at $4.10 and depreciated a bad -0.97%. Since price and SMA200d lines crossed down on Monday, AQST fell $-2.51 per share (-37.97%). Since last January 9th when SMA100d and SMA200d crossed up, AQST price slipped $-2.29 per share (-35.84%).
After climbing for 4 weeks, this week Aquestive Therapeutics plunged a chilling -37.97%, closing at $4.10. Last week AQST boosted an amazing 11.35% in just one week.
Aquestive Therapeutics finally dropped through the support and now is sliding further into fresh lows looking for new supports. This week, Aquestive Therapeutics stock undercut the significant level of the 40-weeks moving average. Stocks under the 40-weeks moving average line are usually not recommended for average traders. Since late December 2019 when SMA20w and SMA40w crossed up, AQST price slipped $-1.44 per share (-25.99%).
Aquestive stock price history
Aquestive stock went public on July 25th, 2018 with a price of $15.101. Since then, AQST stock sliced a -72.80%, with a yearly average of -72.80%.
1: Adjusted price after possible price splits or reverse-splits.
Aquestive stock historical price chart
AQST stock reached 52-week highs on December at $10.00, and all-time highs 2018-09-13 with a price of 20.7.
Aquestive stock price target is $25.50Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 2 price targets for Aquestive stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-22||Wedbush||Set Price Target||n/a||$30.00||-|
|2019-3-15||BMO Capital Markets||Lowers Target||n/a||$21.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAquestive failed analysts on March when it published an Earnings per Share (EPS) of $-0.56 when the market consensus was $-0.91.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a slightly good move of 0.77% to $67.43 M dollars. When comparing 2018 vs 2017, nonetheless, profit margin (that is, the net income divided by revenues) collapsed a -77.66% to -91.02%.
|2016||$52 M||-||$-9.60 M-18.5%||-|
|2017||$67 M||29.22%||$-8.94 M-13.4%||-6.86%|
|2018||$67 M||0.77%||$-61.38 M-91.0%||586.30%|
Quarterly financial resultsAquestive Therapeutics reported $16.82 million in sales for 2018-Q4, a 26.81% improvement compared to previous quarter. Reported quarter earnings marked $-13.94 M with a profit margin of -82.88%. Profit margin climbed a 30.47% compared to previous quarter when profit margin was -113.35%. When comparing sales to same quarter last year, Aquestive sales marked a super good increase and boosted a 37.96%.
|2017-Q1||$16 M||-||$-1.46 M-8.9%||-|
|2017-Q2||$11 M||-32.21%||$-5.90 M-52.9%||304.74%|
|2017-Q4||$12 M||9.45%||$-10.04 M-82.3%||70.26%|
|2018-Q1||$23 M||91.97%||$4.10 M17.5%||-140.83%|
|2018-Q2||$14 M||-40.51%||$-36.49 M-262.0%||-990.29%|
|2018-Q3||$13 M||-4.75%||$-15.04 M-113.3%||-58.79%|
|2018-Q4||$17 M||26.81%||$-13.94 M-82.9%||-7.27%|
Aquestive ownershipWhen you are planning to invest in shares of a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Aquestive Therapeutics, 14.88% of all outstanding shares are owned by its staff.
In case of Aquestive stock, 47.52% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AQST stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Aquestive Therapeutics:
|Market cap||$102.7 M|
|Total shares||25.0 M|
|Float shares||19.1 M|
|- Institutional holdings (%)||47.5%|
|- Insider holdings (%)||14.9%|
|Shares in short selling||0.0%|
|Friday, January 17th, 2020|
|Day range||$4.06 - $4.30|
|Average true range||$0.58|
|50d mov avg||$6.16|
|100d mov avg||$4.81|
|200d mov avg||$4.70|
Aquestive performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Aquestive against in the following table: